BOGLIONE, Lucio
 Distribuzione geografica
Continente #
NA - Nord America 1.094
EU - Europa 722
AS - Asia 364
AF - Africa 26
SA - Sud America 21
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.240
Nazione #
US - Stati Uniti d'America 1.071
IT - Italia 310
DE - Germania 156
CN - Cina 149
FR - Francia 104
GB - Regno Unito 58
IN - India 45
VN - Vietnam 34
JP - Giappone 19
PK - Pakistan 18
CA - Canada 17
KR - Corea 16
IE - Irlanda 13
AU - Australia 12
ID - Indonesia 12
IR - Iran 12
NL - Olanda 12
PE - Perù 12
SG - Singapore 12
EG - Egitto 11
HK - Hong Kong 10
TW - Taiwan 9
AT - Austria 8
ES - Italia 8
RO - Romania 8
RU - Federazione Russa 8
ZA - Sudafrica 8
MX - Messico 6
PL - Polonia 6
CL - Cile 5
TR - Turchia 5
CZ - Repubblica Ceca 4
FI - Finlandia 4
GR - Grecia 4
MY - Malesia 4
CH - Svizzera 3
LT - Lituania 3
RS - Serbia 3
UZ - Uzbekistan 3
BR - Brasile 2
GE - Georgia 2
IL - Israele 2
LV - Lettonia 2
PH - Filippine 2
RW - Ruanda 2
SA - Arabia Saudita 2
TH - Thailandia 2
YE - Yemen 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
BE - Belgio 1
BF - Burkina Faso 1
BG - Bulgaria 1
CO - Colombia 1
KE - Kenya 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
MV - Maldive 1
NE - Niger 1
PT - Portogallo 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
UA - Ucraina 1
VE - Venezuela 1
Totale 2.240
Città #
Fairfield 137
Torino 125
Houston 96
Woodbridge 89
Ashburn 70
Santa Cruz 66
Ann Arbor 58
Beijing 57
Buffalo 53
Wilmington 52
Cambridge 43
Seattle 40
Dong Ket 21
Munich 21
Chicago 15
Boardman 14
University Park 14
Dublin 13
Lima 12
Nanjing 11
Shanghai 11
Wuhan 11
Milan 10
Nürnberg 10
Bengaluru 9
Bologna 9
Clearwater 9
Columbus 9
Indianapolis 9
Leawood 9
Ottawa 9
Rome 9
Taipei 9
Amsterdam 8
Dallas 8
Los Angeles 8
Mountain View 8
Singapore 8
Vienna 8
Muizenberg 7
Nutley 7
San Diego 7
Suzhou 7
Toronto 7
Turin 7
Guangzhou 6
Hyderabad 6
Lake Forest 6
Liverpool 6
Pisa 6
Warsaw 6
Cairo 5
Duncan 5
Hartford 5
Las Vegas 5
Phoenix 5
Windsor 5
Hangzhou 4
Hefei 4
Islamabad 4
Jakarta 4
Karachi 4
Minneapolis 4
Naples 4
New Delhi 4
Qingdao 4
Tianjin 4
Tokyo 4
Austin 3
Bangalore 3
Berlin 3
Boulder 3
Ho Chi Minh City 3
Madrid 3
Mumbai 3
Negar 3
Osaka 3
Riva 3
San Jose 3
Southend 3
Washington 3
Anniston 2
Athens 2
Bandung 2
Bangkok 2
Baotou 2
Bristol 2
Catanzaro 2
Central 2
Central District 2
Changshahsien 2
Cheyenne 2
Chuo 2
Cluj-napoca 2
Des Moines 2
Dudenhofen 2
Esslingen am Neckar 2
Fazal 2
Fleming Island 2
Frankfurt am Main 2
Totale 1.407
Nome #
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy, file e27ce42c-3b01-2581-e053-d805fe0acbaa 403
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1., file e27ce426-fb81-2581-e053-d805fe0acbaa 281
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients., file e27ce42a-76ff-2581-e053-d805fe0acbaa 257
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study, file e27ce42b-11e1-2581-e053-d805fe0acbaa 239
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B, file e27ce42d-32e8-2581-e053-d805fe0acbaa 204
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir, file e27ce428-c2c4-2581-e053-d805fe0acbaa 185
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy, file e27ce42e-fdc1-2581-e053-d805fe0acbaa 95
Co-infection with other respiratory pathogens in COVID-19 patients, file e27ce431-c341-2581-e053-d805fe0acbaa 93
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry, file e27ce432-46be-2581-e053-d805fe0acbaa 79
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients, file e27ce427-eef7-2581-e053-d805fe0acbaa 75
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon., file e27ce42a-709f-2581-e053-d805fe0acbaa 71
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir., file e27ce427-eda3-2581-e053-d805fe0acbaa 51
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia., file e27ce427-ed9c-2581-e053-d805fe0acbaa 46
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy, file e27ce432-7646-2581-e053-d805fe0acbaa 43
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon, file e27ce42a-3c32-2581-e053-d805fe0acbaa 38
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma, file e27ce433-9ce4-2581-e053-d805fe0acbaa 31
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing, file e27ce42a-683f-2581-e053-d805fe0acbaa 10
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy, file e27ce434-baaa-2581-e053-d805fe0acbaa 10
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms., file e27ce42a-7eca-2581-e053-d805fe0acbaa 9
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study, file e27ce42c-25e6-2581-e053-d805fe0acbaa 8
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study, file e27ce42d-7321-2581-e053-d805fe0acbaa 6
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients, file e27ce42c-9b03-2581-e053-d805fe0acbaa 5
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells, file e27ce428-bc7b-2581-e053-d805fe0acbaa 4
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon., file e27ce428-befb-2581-e053-d805fe0acbaa 4
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients., file e27ce42a-7700-2581-e053-d805fe0acbaa 4
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B, file e27ce42a-e7bb-2581-e053-d805fe0acbaa 4
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms, file e27ce42b-ee7b-2581-e053-d805fe0acbaa 4
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients, file e27ce42c-45f1-2581-e053-d805fe0acbaa 4
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis, file e27ce42d-0fbb-2581-e053-d805fe0acbaa 4
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy, file e27ce42d-7323-2581-e053-d805fe0acbaa 4
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir., file e27ce432-2134-2581-e053-d805fe0acbaa 4
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients, file e27ce426-fbb6-2581-e053-d805fe0acbaa 3
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner., file e27ce428-ca85-2581-e053-d805fe0acbaa 3
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools., file e27ce42a-6f58-2581-e053-d805fe0acbaa 3
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors, file e27ce42c-1a28-2581-e053-d805fe0acbaa 3
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs, file e27ce42c-586b-2581-e053-d805fe0acbaa 3
Flecainide plasma level modifications during the ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C, file e27ce430-a633-2581-e053-d805fe0acbaa 3
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients, file e27ce426-edae-2581-e053-d805fe0acbaa 2
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia., file e27ce428-b3bf-2581-e053-d805fe0acbaa 2
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients, file e27ce428-bc16-2581-e053-d805fe0acbaa 2
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, file e27ce428-c2bf-2581-e053-d805fe0acbaa 2
The Role of IL28B Genotype in HCV-RNA Baseline Levels, file e27ce42a-a509-2581-e053-d805fe0acbaa 2
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma, file e27ce42a-c0ee-2581-e053-d805fe0acbaa 2
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B, file e27ce42a-e55b-2581-e053-d805fe0acbaa 2
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4, file e27ce42b-6610-2581-e053-d805fe0acbaa 2
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3, file e27ce42b-e705-2581-e053-d805fe0acbaa 2
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens, file e27ce42d-1f65-2581-e053-d805fe0acbaa 2
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment, file e27ce428-b64f-2581-e053-d805fe0acbaa 1
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage, file e27ce428-b6ac-2581-e053-d805fe0acbaa 1
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy, file e27ce428-b6bc-2581-e053-d805fe0acbaa 1
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics, file e27ce428-be99-2581-e053-d805fe0acbaa 1
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients, file e27ce428-bf03-2581-e053-d805fe0acbaa 1
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms., file e27ce428-c4ef-2581-e053-d805fe0acbaa 1
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir, file e27ce428-c57f-2581-e053-d805fe0acbaa 1
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes., file e27ce428-cc1c-2581-e053-d805fe0acbaa 1
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia, file e27ce42a-8c84-2581-e053-d805fe0acbaa 1
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon, file e27ce42a-a508-2581-e053-d805fe0acbaa 1
Role of intravenous immunoglobulin administration in Japanese encephalitis., file e27ce42a-d91e-2581-e053-d805fe0acbaa 1
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?, file e27ce42a-de62-2581-e053-d805fe0acbaa 1
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C, file e27ce42b-6f94-2581-e053-d805fe0acbaa 1
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study, file e27ce42b-9b4f-2581-e053-d805fe0acbaa 1
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia, file e27ce42b-b4ec-2581-e053-d805fe0acbaa 1
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients, file e27ce42b-b4ed-2581-e053-d805fe0acbaa 1
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study, file e27ce42b-ee78-2581-e053-d805fe0acbaa 1
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients, file e27ce42b-f4a4-2581-e053-d805fe0acbaa 1
Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis, file e27ce42d-1df5-2581-e053-d805fe0acbaa 1
Combination therapy in chronic hepatitis B: what are the real benefits?, file e27ce42d-485d-2581-e053-d805fe0acbaa 1
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series, file e27ce42e-1c19-2581-e053-d805fe0acbaa 1
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D, file e27ce431-e548-2581-e053-d805fe0acbaa 1
Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia., file e27ce431-ee61-2581-e053-d805fe0acbaa 1
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes., file e27ce432-0dc8-2581-e053-d805fe0acbaa 1
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers, file e27ce433-4c11-2581-e053-d805fe0acbaa 1
Totale 2.338
Categoria #
all - tutte 3.612
article - articoli 0
book - libri 0
conference - conferenze 416
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.028


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201947 0 0 0 0 0 0 0 0 0 0 0 47
2019/2020463 42 27 32 56 40 29 39 48 51 40 34 25
2020/2021425 35 34 27 22 24 37 28 31 19 51 72 45
2021/2022483 47 45 51 67 46 24 39 21 14 22 80 27
2022/2023316 20 29 74 41 31 30 39 10 14 12 14 2
2023/2024100 2 4 10 6 10 4 12 21 5 8 16 2
Totale 2.338